New combo therapy targets Hard-to-Treat breast cancer

NCT ID NCT04837209

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 28 times

Summary

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. The trial enrolls 32 adults with advanced disease. The goal is to see if this combination can shrink tumors and control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, 20016, United States

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.